T-cell recognition of human melanoma antigens. 1993

Y Kawakami, and M I Nishimura, and N P Restifo, and S L Topalian, and B H O'Neil, and J Shilyansky, and J R Yannelli, and S A Rosenberg
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

The adoptive transfer of tumor-infiltrating lymphocytes (TILs) with interleukin-2 (IL-2) has antitumor activity in some patients with metastatic melanoma. We have analyzed molecular mechanisms of TIL recognition of human melanoma. Some cultured TILs specifically lysed autologous and some allogeneic melanomas sharing a variety of class I major histocompatibility complex (MHC) molecules. HLA-A2-restricted melanoma-specific TILs lysed many HLA-A2+ melanoma cell lines from different patients but failed to lyse HLA-A2- melanoma and HLA-A2+ nonmelanoma cell lines. However, these TILs were capable of lysing many naturally HLA-A2- melanomas after introduction of the HLA-A2.1 gene by vaccinia virus. These results indicate that shared melanoma antigens (Ag) are expressed in melanomas regardless of their human leukocyte antigen types. In order to identify these shared melanoma Ags, we have tested some known proteins expressed in melanoma. Expression of tyrosinase or HMB45 Ag correlated with lysis of TILs. We are also attempting to isolate antigenic peptides by high performance liquid chromatography separation and genes encoding melanoma Ag by cDNA expression cloning. The T-cell component of the antimelanoma response was also analyzed by determining the genetic structure of the T-cell receptor (TCR) used by melanoma TILs. However, we did not observe common TCR variable region usage by different melanoma TILs. We could establish melanoma cell clones and lines resistant to TIL lysis due to the absence of or defects in the expression of Ag, MHC, or beta 2-microglobulin molecules. These data indicate multiple mechanisms for melanoma escape from T-cell immunosurveillance.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D000937 Antigen-Antibody Reactions The processes triggered by interactions of ANTIBODIES with their ANTIGENS. Antigen Antibody Reactions,Antigen-Antibody Reaction,Reaction, Antigen-Antibody,Reactions, Antigen-Antibody
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D016246 Lymphocytes, Tumor-Infiltrating Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer. Tumor Infiltrating Lymphocyte,Tumor-Derived Activated Cell,Tumor-Derived Activated Cells,Tumor-Infiltrating Lymphocyte,Tumor-Infiltrating Lymphocytes,Activated Cell, Tumor-Derived,Activated Cells, Tumor-Derived,Infiltrating Lymphocyte, Tumor,Infiltrating Lymphocytes, Tumor,Lymphocyte, Tumor Infiltrating,Lymphocyte, Tumor-Infiltrating,Lymphocytes, Tumor Infiltrating,Tumor Derived Activated Cell,Tumor Derived Activated Cells,Tumor Infiltrating Lymphocytes

Related Publications

Y Kawakami, and M I Nishimura, and N P Restifo, and S L Topalian, and B H O'Neil, and J Shilyansky, and J R Yannelli, and S A Rosenberg
March 2000, Journal of cellular physiology,
Y Kawakami, and M I Nishimura, and N P Restifo, and S L Topalian, and B H O'Neil, and J Shilyansky, and J R Yannelli, and S A Rosenberg
May 1996, Cancer research,
Y Kawakami, and M I Nishimura, and N P Restifo, and S L Topalian, and B H O'Neil, and J Shilyansky, and J R Yannelli, and S A Rosenberg
January 1997, International journal of clinical & laboratory research,
Y Kawakami, and M I Nishimura, and N P Restifo, and S L Topalian, and B H O'Neil, and J Shilyansky, and J R Yannelli, and S A Rosenberg
April 2001, Current opinion in infectious diseases,
Y Kawakami, and M I Nishimura, and N P Restifo, and S L Topalian, and B H O'Neil, and J Shilyansky, and J R Yannelli, and S A Rosenberg
January 2006, Advances in immunology,
Y Kawakami, and M I Nishimura, and N P Restifo, and S L Topalian, and B H O'Neil, and J Shilyansky, and J R Yannelli, and S A Rosenberg
June 1994, Cancer immunology, immunotherapy : CII,
Y Kawakami, and M I Nishimura, and N P Restifo, and S L Topalian, and B H O'Neil, and J Shilyansky, and J R Yannelli, and S A Rosenberg
June 2001, The Keio journal of medicine,
Y Kawakami, and M I Nishimura, and N P Restifo, and S L Topalian, and B H O'Neil, and J Shilyansky, and J R Yannelli, and S A Rosenberg
September 1995, The European respiratory journal. Supplement,
Y Kawakami, and M I Nishimura, and N P Restifo, and S L Topalian, and B H O'Neil, and J Shilyansky, and J R Yannelli, and S A Rosenberg
June 1987, Human immunology,
Y Kawakami, and M I Nishimura, and N P Restifo, and S L Topalian, and B H O'Neil, and J Shilyansky, and J R Yannelli, and S A Rosenberg
August 1996, Current opinion in immunology,
Copied contents to your clipboard!